Skip to main content

Table 2 Summary of suspected treatment related adverse events

From: Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses

  Summary of adverse events occurred within cycle 1
  All grade N = 32 No. (%) Grade 3 N = 32 No. (%)
Diarrhea 8 ( 25) 0 (0)
Nausea 13 ( 41) 0 (0)
Vomitting 9 ( 28) 0 (0)
Anaemia 6 ( 19) 2 ( 6)
Neutropenia 6 ( 19) 6 ( 19)
Leukopenia 3 ( 9) 3 ( 9)
Thrombocytopenia 3 ( 9) 3 ( 9)
Febrile neutropenia 2 ( 6) 2 ( 6)
Lethargy 12 ( 38) 4 ( 13)
Syncope 1 ( 3) 1 ( 3)
Chills 2 ( 6) 1 ( 3)
Hepatorenal failure 1 ( 3) 1 ( 3)
Neutropenic sepsis 1 ( 3) 1 ( 3)
Back pain 1 ( 3) 1 ( 3)
Dyspnoea 1 ( 3) 1 ( 3)